{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058675","form_type":"8-K","ticker":null,"cik":"0001082038","company_name":"DURECT CORP","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.205551+00:00","generated_at":"2026-06-02T01:53:46.324178+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DURECT reports Q1 net loss $7.6M; FDA supports single pivotal trial for larsucosterol in AH","bullets":["FDA feedback supports single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis; NDA filing possible if successful.","Q1 2024 total revenues $1.8M, net loss $7.6M vs revenues $2.1M, net loss $12.0M in Q1 2023.","Cash and investments $21.6M at Mar 31, 2024, down from $29.8M at Dec 31, 2023; debt $14.6M.","Late-breaking oral presentation of AHFIRM Phase 2b data accepted at EASL Congress 2024 in June."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058675","json":"https://secwatch.observer/filing/0000950170-24-058675.json","markdown":"https://secwatch.observer/filing/0000950170-24-058675.md","text":"https://secwatch.observer/filing/0000950170-24-058675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/0000950170-24-058675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/drrx-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:53:46.324178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"496cccd4641e2afce3468ebdd5f03e93e423c44a","claim":"DURECT CORP reported three months ended March 31, 2024 results: revenue $1.8 million, net income $7.6 million.","evidence_excerpt":"2b AHFIRM trial, which evaluated the safety and efficacy of larsucosterol as a treatment for patients with severe AH. Financial Highlights for Q1 2024: • Total revenues were $1.8 million and net loss was $7.6 million for the three months ended March 31, 2024 compared to total revenues of $2.1 million and net loss of $12.0 million for the three months ended March","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/0000950170-24-058675-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$1.8 million"},{"label":"Net income","value":"$7.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}